undamentalytics Newsletter
Sign in

Faeth Therapeutics, Inc. (FTH) stock

Add to watchlist

Add holding +

NASDAQ: FTH Nasdaq Biotechnology Next results ~November 3, 2026

Faeth Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 4 selling49 purchases and 45 sales by directors and officers, last 12 monthsInsider trades

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 93.2% while net income fell 775.6%: a 682pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 14.8% in a year, so each share owns more of the business.

Things to watch

  • Results due soon. Results are expected around 13 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 219% and a beta of 2.4 against the S&P 500.
  • Short interest rising. Shares sold short rose 76% in a month to 9.1% of tradable shares.

Latest results

Earnings per share
-$2.84 against an average estimate of -$4.76: beat by 40.3%
Share reaction
-10.1% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Next report
November 3, 2026; average EPS estimate -$0.71

Faeth Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.9%
  • 1 week+14.3%
  • 1 month-32.2%
  • This year+80.2%
  • 1 year+109.7%
  • 5 years-89.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-24.84

Earnings

Last results
August 4, 2026
Next results (est.)
November 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Leadership
  3. Results
  4. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Faeth Therapeutics, Inc. valuation models and calculator

No model value for Faeth Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Faeth Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10%: the 10-year Treasury yield (4.9%) plus a beta of 1.11 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no positive revenue in the latest twelve months
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Faeth Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, before the open. Analysts expect revenue of $0 and EPS of −$0.71 (range −$0.77 to −$0.66) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$9.97 — — 0%
Next −$3.67 +63% — 0%

How the EPS forecast has moved

In the last 30 days, 1 analyst raised Faeth Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Faeth Therapeutics, Inc., last 90 days
−$15.00 −$10.00 −$5.00 $0.00 60 days ago 30 days ago 7 days ago Now Current fiscal year, 60 days ago: −$11.98 Current fiscal year, 30 days ago: −$13.78 Current fiscal year, 7 days ago: −$9.97 Current fiscal year, Now: −$9.97 −$9.97 Next fiscal year, 60 days ago: −$4.96 Next fiscal year, 30 days ago: −$4.49 Next fiscal year, 7 days ago: −$3.67 Next fiscal year, Now: −$3.67 −$3.67

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
60 days ago −$11.98−$4.96
30 days ago −$13.78−$4.49
7 days ago −$9.97−$3.67
Now −$9.97−$3.67

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$4.76 −$2.84 +40.3%
Mar 2026 −$0.62 −$131.45 −21101.6%
Dec 2025 −$4.81 −$3.74 +22.2%
Sept 2025 −$4.11 −$3.62 +11.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

15 analysts, Oct 2026
Buy15100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202631215
  2. Sep 202631114
  3. Aug 20263912
  4. Jul 20262810

Counts of recommendations published by analysts covering Faeth Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
9.1%
of tradable shares
Days to cover
5.41
at average volume
Short interest, 1 month
+76%
to October 15, 2026
Held by institutions
81%
of shares
Held by insiders
4.9%
of shares
Employees
29
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
FTH−74%−54%−29%+9%+80%
Industry peers (median)−56%−17%−28%−5%−27%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
FTH25%25%42%42%55%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
FTH−78%−71%−78%−55%−69%
S&P 500−25%−10%−8%−19%−9%

Worst fall since February 4, 2021: 99% from February 8, 2021 to April 4, 2025. Getting back needed a 7772% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$7.89 – $40.05
From 52-week high
−52.0%
vs 50-day average
−32.6%
vs 200-day average
−23.6%
Volatility (1 year)
219%
Beta vs S&P 500
2.35

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±9.1%
After a week
4 up, 8 down
typical move ±11.7%
After a month
4 up, 8 down
typical move ±19.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 −10.1% +1.6% +9.7% +43.1%
May 15, 2026 +0.5% −1.3% −10.2% −26.7%
March 30, 2026 +13.9% +2.6% +9.1% +2.2%
November 14, 2025 −9.8% −0.9% −3.3% −10.4%
August 5, 2025 −10.4% +0.3% −12.6% +1.9%
May 6, 2025 −6.7% −0.4% −15.2% −14.0%
March 28, 2025 −8.6% −1.4% −32.9% −11.8%
November 14, 2024 −14.7% −1.9% −9.0% −18.8%
August 6, 2024 +4.1% +0.2% +2.6% −3.3%
May 9, 2024 −17.9% +0.7% −13.6% −63.6%
February 28, 2024 +10.4% +0.2% +21.0% +36.4%
November 7, 2023 +2.1% +0.4% −0.7% −4.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Who owns it

13F filings for June 30, 2026
Reported value
$334M
Institutions reporting
45
Shares held vs prior quarter
▲ 514.7%
Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Montanova Capital, LLC $50.5M 2.0M 15.1% ▲ 5747.1%
Avoro Capital Advisors LLC $36.1M 1.4M 10.8% New
Baker Bros. Advisors LP $32.2M 1.3M 9.6% New
Balyasny Asset Management L.P. $26.1M 1.0M 7.8% ▲ 6331.3%
RA Capital Management, L.P. $18.1M 722K 5.4% New
Vivo Capital, LLC $18.1M 722K 5.4% 0.0%
Logos Global Management LP $18.1M 722K 5.4% ▲ 2306.7%
Fairmount Funds Management LLC $18.1M 722K 5.4% New
Caligan Partners LP $15.7M 629K 4.7% ▲ 399.6%
B Group, Inc. $15.3M 610K 4.6% New
Trails Edge Capital Partners, LP $12.9M 515K 3.9% ▲ 312.3%
Franklin Resources Inc $12.4M 495K 3.7% ▲ 270.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Faeth Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $2.5M 49 trades by 4 insiders, last 12 months Insider sales History → $2.3M 45 trades by 4 insiders · 0% under pre-set plans
Net ▲ $250,436 net buying
Insider Date Trade Shares Price Value
Stephenson Brian C Chief Financial Officer July 1, 2026 Buy 4,400 $23.40 $102,960
Stephenson Brian C Chief Financial Officer July 1, 2026 Buy 600 $24.22 $14,532
Stephenson Brian C Chief Financial Officer June 30, 2026 Buy 4,255 $24.98 $106,290
Stephenson Brian C Chief Financial Officer June 30, 2026 Buy 1,910 $22.95 $43,834
Stephenson Brian C Chief Financial Officer June 30, 2026 Buy 1,638 $23.88 $39,115
Stephenson Brian C Chief Financial Officer June 29, 2026 Buy 831 $23.34 $19,396
Stephenson Brian C Chief Financial Officer June 26, 2026 Buy 580 $23.61 $13,694
Stephenson Brian C Chief Financial Officer June 26, 2026 Buy 4,212 $24.90 $104,879
Stephenson Brian C Chief Financial Officer June 26, 2026 Buy 1,358 $25.55 $34,697
Stephenson Brian C Chief Financial Officer June 26, 2026 Buy 100 $26.39 $2,639
Stephenson Brian C Chief Financial Officer June 24, 2026 Buy 2,891 $25.22 $72,911
Stephenson Brian C Chief Financial Officer June 24, 2026 Buy 3,000 $25.98 $77,940

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 13, 2026 estimated from the company's past filing pattern, not announced

  • August 4, 2026
  • May 15, 2026
  • March 30, 2026
  • November 14, 2025
  • August 5, 2025
  • May 6, 2025

Recent SEC filings

Data status

When each part of this page on Faeth Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Faeth Therapeutics, Inc. in brief

What does Faeth Therapeutics, Inc. do?
Faeth Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Faeth Therapeutics, Inc.'s stock ticker?
Faeth Therapeutics, Inc. trades under the ticker FTH on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Faeth Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Montanova Capital, LLC, Avoro Capital Advisors LLC and Baker Bros. Advisors LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Faeth Therapeutics, Inc. stock?
Over the last 12 months, Faeth Therapeutics, Inc.'s directors and officers reported 49 open-market purchases and 45 sales on Form 4. The insider trading page charts every trade.
When is Faeth Therapeutics, Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Faeth Therapeutics, Inc. announces its own schedule.